Thu, Mar 27, 8:50 PM (30 days ago)
### Summary of Bio-Path Holdings, Inc. (BPTH) Annual Report **Financial Performance:** - **Revenue:** No significant revenue reported for the years ended December 31, 2024 and 2023. - **Net Loss:** $9.9 million for 2024, a decrease of $6.2 million compared to $16.1 million in 2023. - **Net Loss per Share:** $4.12 per share for 2024, compared to $33.63 per share for 2023. - **Cash Balance:** $1.2 million at December 31, 2024, an increase of $0.1 million compared to December 31, 2023. **Operating Expenses:** - **Research and Development:** $7.3 million for 2024, a decrease of $4.3 million compared to $11.6 million in 2023. - **General and Administrative:** $4.7 million for 2024, an increase of $0.5 million compared to $4.2 million in 2023. **Strategic Overview:** - **Drug Candidates:** Four drug candidates in development: BP1001 (prexigebersen), BP1002 (Liposomal Bcl-2), BP1003 (Liposomal STAT3), and BP1001-A. - **Clinical Trials:** Ongoing Phase 2 trials for BP1001 in AML, Phase 1/1b trials for BP1002 and BP1001-A, and IND-enabling studies for BP1003. - **Future Outlook:** Plans to expand clinical trials, seek FDA expedited programs, and evaluate market expansion in Europe. **Risk Factors:** - **Financial Condition:** Significant operating losses and reliance on additional capital. - **Market Position:** Highly competitive pharmaceutical and biotechnology industry. - **Regulatory:** Extensive governmental regulations and potential delays in approvals. **Future Outlook:** - **Capital Requirements:** Continued need for substantial additional capital to fund operations and clinical trials. - **Market Position:** Potential market acceptance challenges and competition from other drug candidates. **Market Position Changes:** - **Delisting:** Nasdaq delisting and trading on the OTCQB Venture Market. - **Future Prospects:** Uncertainty in raising additional capital and maintaining market position.